Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Shares Issued (2020 - 2025)

Tarsus Pharmaceuticals has reported Shares Issued over the past 6 years, most recently at -$134.8 million for Q4 2025.

  • Quarterly results put Shares Issued at -$134.8 million for Q4 2025, down 1737.76% from a year ago — trailing twelve months through Sep 2025 was $143.0 million (up 246.44% YoY), and the annual figure for FY2024 was $9.4 million, up 1481.93%.
  • Shares Issued for Q4 2025 was -$134.8 million at Tarsus Pharmaceuticals, down from $133.7 million in the prior quarter.
  • Over the last five years, Shares Issued for TARS hit a ceiling of $133.7 million in Q3 2025 and a floor of -$134.8 million in Q4 2025.
  • Median Shares Issued over the past 5 years was $222000.0 (2022), compared with a mean of $701466.7.
  • Peak annual rise in Shares Issued hit 80894.31% in 2023, while the deepest fall reached 27313.5% in 2023.
  • Tarsus Pharmaceuticals' Shares Issued stood at $103000.0 in 2021, then soared by 252.43% to $363000.0 in 2022, then plummeted by 27313.5% to -$98.8 million in 2023, then skyrocketed by 108.33% to $8.2 million in 2024, then crashed by 1737.76% to -$134.8 million in 2025.
  • The last three reported values for Shares Issued were -$134.8 million (Q4 2025), $133.7 million (Q3 2025), and $1.1 million (Q2 2025) per Business Quant data.